000131894 001__ 131894
000131894 005__ 20240731103415.0
000131894 0247_ $$2doi$$a10.1177/20552173231169475
000131894 0248_ $$2sideral$$a137002
000131894 037__ $$aART-2023-137002
000131894 041__ $$aeng
000131894 100__ $$aSainz de la Maza, Susana
000131894 245__ $$aDetecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach
000131894 260__ $$c2023
000131894 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131894 5203_ $$aDisability accrual is mainly driven by progression independent of relapse activity, which is present even in early stages of relapsing-remitting multiple sclerosis (RRMS) and sometimes overlooked. This multicenter, non-interventional study evaluated whether patient-reported outcomes measures (PROMs) could capture disability in 189 early-stage RRMS patients (mean age: 36.1 ± 9.4 years, 71.4% female, mean disease duration: 1.4 ± 0.8 years, median EDSS: 1.0). The 9-Hole Peg Test (9-HPT), NeuroQoL Upper Extremity (NeuroQoL-UE), Timed 25-Foot Walk (T25-FW), Multiple Sclerosis Walking Scale (MSWS-12), Symbol Digit Modalities Test (SDMT), and Perceived Deficits Questionnaire (PDQ-5) were used to assess hand function, gait, and cognition, respectively. These functions were at least mildly affected in this early-stage population, finding significant correlations between PROMs and clinical assessments. PROMs could enable early-stage RRMS patients to communicate their perceived disability in different domains, assisting clinicians in disease monitoring and decision making.
000131894 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000131894 592__ $$a0.959$$b2023
000131894 593__ $$aNeurology (clinical)$$c2023$$dQ2
000131894 593__ $$aCellular and Molecular Neuroscience$$c2023$$dQ3
000131894 594__ $$a4.7$$b2023
000131894 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131894 700__ $$aGómez-Ballesteros, Rocío
000131894 700__ $$aBorges, Mónica
000131894 700__ $$aMartín-Martínez, Jesús
000131894 700__ $$aSotoca, Javier
000131894 700__ $$aAlonso, Ana
000131894 700__ $$aCaminero, Ana B.
000131894 700__ $$aBorrega, Laura
000131894 700__ $$aSánchez-Menoyo, José L.
000131894 700__ $$aBarrero-Hernández, Francisco J.
000131894 700__ $$aCalles, Carmen
000131894 700__ $$aBrieva, Luis
000131894 700__ $$aBlasco-Quílez, María R.
000131894 700__ $$aDotor García-Soto, Julio
000131894 700__ $$aCampo-Amigo, María del
000131894 700__ $$aNavarro-Cantó, Laura
000131894 700__ $$aAgüera, Eduardo
000131894 700__ $$0(orcid)0000-0002-1756-5492$$aGarcés-Redondo, Moisés$$uUniversidad de Zaragoza
000131894 700__ $$aCarmona, Olga
000131894 700__ $$aGabaldón-Torres, Laura
000131894 700__ $$aForero, Lucía
000131894 700__ $$aHervàs, Mariona
000131894 700__ $$aMedrano, Nicolás
000131894 700__ $$aMaurino, Jorge
000131894 700__ $$aCastillo-Triviño, Tamara
000131894 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000131894 773__ $$g9, 2 (2023), [7 pp.]$$tMultiple Sclerosis Journal - Experimental, Translational and Clinical$$x2055-2173
000131894 8564_ $$s744576$$uhttps://zaguan.unizar.es/record/131894/files/texto_completo.pdf$$yVersión publicada
000131894 8564_ $$s2595322$$uhttps://zaguan.unizar.es/record/131894/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131894 909CO $$ooai:zaguan.unizar.es:131894$$particulos$$pdriver
000131894 951__ $$a2024-07-31-10:06:19
000131894 980__ $$aARTICLE